Quantcast

Industry news that matters to you.  Learn more

Crescendo Bioscience, Inc. Announces the U.S. Launch of the First Multi-biomarker Blood Test for Rheumatoid Arthritis Disease Activity

Crescendo Bioscience announced today the commercial launch of Vectra DA, its first-in-class multi-biomarker blood test designed to aid physicians in managing patients with rheumatoid arthritis (RA). Vectra DA analyzes 12 key serum biomarkers to produce a single objective score that quantifies RA disease activity. Launched today at the ACR/ARHP Annual Scientific Meeting , Vectra DA is now available to physicians in 47 states (laboratory licensure has been applied for in Maryland and Rhode Island and is planned for New York).

Edimer Pharmaceuticals Presents Study Results on Non-Invasive Sweat Gland Analysis as a Biomarker in XLHED Patients

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced key findings of a study exploring novel approaches to the assessment of sweat function in males with XLHED. Affected individuals lack a normal sweat response, placing them at life-long risk for clinically-significant hyperthermia. The study reported on the use of non-invasive technologies for quantitative sweat function, and correlated these results with the nature and location of ectodysplasin A (EDA) gene defects associated with XLHED. Data analysis confirmed a consistent, quantifiable defect in sweat gland function as a disease biomarker in XLHED patients, even in the setting of normal sweat pore counts. The study outcomes were reported at the 60th Annual Meeting of the American Society of Human Genetics (ASHG) in Washington, D.C.

Karmanos Cancer Institute Uses Definiens Tissue Studio for Biomarker Development

Definiens, the number one Health Image Intelligence company, today announced that the Barbara Ann Karmanos Cancer Institute in Detroit is using Definiens image analysis software in a new approach to cancer diagnosis and biomarker development. The Karmanos Cancer Institute is applying Definiens Tissue Studio 2.0TM, the newest version of the company’s leading image analysis software for digital pathology, to automate tissue section and microarray analysis. Led by Gerold Bepler, M.D., Ph.D., president and CEO of the Karmanos Cancer Institute, the research team will replace tedious manual analysis processes with automated image analysis to more reliably develop biomarkers that facilitate patient stratification models for personalized medicine applications.

Area Biotech Company Banyan Biomarkers On Cutting Edge

The founders of Banyan Biomarkers describe the Alachua-based research firm as a “Gator-made company.”

Banyan made news recently when it was awarded a $26.3 million Department of Defense contract to develop a diagnostic blood test for traumatic brain injury, or TBI. The company has been studying “biomarkers,” or proteins in the blood produced by an injured brain.

UK launches Stratified Medicines Innovation Platform

The UK’s Technology Strategy Board has launched a new programme designed to place the country at the forefront of medicines tailored to smaller and more responsive subsets of patients.

The Stratified Medicines Innovation Platform will bring together researchers, policymakers and the private sector in an initiative drawing on government funding of over £50 million for innovative research and development in areas such as tumour profiling to improve cancer care and biomarker development to enhance drug effectiveness.